Id: acc0040
Group: 1sens
Protein: DMAP1
Gene Symbol: DMAP1
Protein Id: Q9NPF5
Protein Name: DMAP1_HUMAN
PTM: phosphorylation
Site: Tyr246
Site Sequence: TPEQVAEEEYLLQELRKIEAR
Disease Category: Cancer
Disease: Pancreas Cancer
Disease Subtype: adenocarcinoma
Disease Cellline: PANC-1
Disease Info:
Drug: paclitaxel
Drug Info: "Paclitaxel is a plant-derived alkaloid and potent antineoplastic agent that stabilizes microtubules to inhibit cancer cell division, primarily used in the treatment of ovarian, breast, and lung cancers. "
Effect: resist
Effect Info: DMAP1 Y246 phosphorylation counteracts the antitumor activity of paclitaxel in vivo.
Note:
Score: 5.0
Pubmed(PMID): 30553276
Sentence Index:
Sentence:

Sequence & Structure:

MATGADVRDILELGGPEGDAASGTISKKDIINPDKKKSKKSSETLTFKRPEGMHREVYALLYSDKKDAPPLLPSDTGQGYRTVKAKLGSKKVRPWKWMPFTNPARKDGAMFFHWRRAAEEGKDYPFARFNKTVQVPVYSEQEYQLYLHDDAWTKAETDHLFDLSRRFDLRFVVIHDRYDHQQFKKRSVEDLKERYYHICAKLANVRAVPGTDLKIPVFDAGHERRRKEQLERLYNRTPEQVAEEEYLLQELRKIEARKKEREKRSQDLQKLITAADTTAEQRRTERKAPKKKLPQKKEAEKPAVPETAGIKFPDFKSAGVTLRSQRMKLPSSVGQKKIKALEQMLLELGVELSPTPTEELVHMFNELRSDLVLLYELKQACANCEYELQMLRHRHEALARAGVLGGPATPASGPGPASAEPAVTEPGLGPDPKDTIIDVVGAPLTPNSRKRRESASSSSSVKKAKKP

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

DMAP1-Ser448
Cancer Intensity
BRCA
COAD -0.074
HGSC
ccRCC
GBM
HNSC
LUAD -0.961
LUSC
non_ccRCC
PDAC
UCEC 1.035
DMAP1-Ser454
Cancer Intensity
BRCA -0.919
COAD -0.555
HGSC -1.588
ccRCC 0.341
GBM 0.124
HNSC 0.207
LUAD -0.001
LUSC 0.177
non_ccRCC 2.466
PDAC -0.075
UCEC -0.179
DMAP1-Ser456
Cancer Intensity
BRCA 1.407
COAD -0.955
HGSC
ccRCC
GBM -0.283
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.169
DMAP1-Ser457
Cancer Intensity
BRCA 1.135
COAD
HGSC
ccRCC
GBM -0.75
HNSC
LUAD -0.385
LUSC
non_ccRCC
PDAC
UCEC
DMAP1-Ser458
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
DMAP1-Thr409
Cancer Intensity
BRCA
COAD 0.463
HGSC -1.148
ccRCC
GBM
HNSC 0.685
LUAD
LUSC
non_ccRCC
PDAC
UCEC
DMAP1-Thr445
Cancer Intensity
BRCA 1.717
COAD 0.16
HGSC -1.973
ccRCC 0.393
GBM 0.009
HNSC 0.816
LUAD -0.019
LUSC -0.091
non_ccRCC -1.446
PDAC 0.464
UCEC -0.031

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
Y 246 U Pancreatic carcinoma Phosphorylation 30553276

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: